RAIN - Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Rain Oncology Inc. (RAIN) | Benzinga

LOS ANGELES, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP ("GPM") reminds investors of the upcoming September 12, 2023 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Rain Oncology Inc. ("Rain" or the "Company") (NASDAQ:RAIN) securities between July 20, 2021 and May 19, 2023, inclusive (the "Class Period").

If you suffered a loss on your Rain investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws, you can submit your contact information at www.glancylaw.com/cases/Rain-Oncology-Inc/. You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at shareholders@glancylaw.com to learn more about your rights.

On May 22, 2023, Rain announced the Phase 3 trial results of its antitumor drug, milademetan, revealing that the trial "did not meet its primary endpoint of progression ...

RAIN)>Full story available on Benzinga.com